Member Info for gjbrandon

We will be providing further updates in due course. It is still early in development and preliminary results are to be published over the coming weeks.

If the Microtox NS system is adapted the potential for detection will be instant, not allowing access to the facility.

@PL75. A Practical Question (that is more than 1 question)

When / how do you determine that an outbreak has passed?
The objective is to provide a daily high-viral load detection test which will tell you where you are in the infectious period, or whether you are a super-spreader. This can only be done using nanotechnology detection using AI. The more that it is used, the greater the accuracy, and eventually could even predict the likelihood of breakout based on data before they breakout.

Will the system be quantitative allowing viral loads to be charted? Yes

LFD's may play a role, but they are individual, rather than community based. This will be explained as we progress further.

Would the affimers need replacing more frequently etc? Yes, we only need Affimers and Aptamers for the above proposed solution

@SNewby, your question made me laugh, and I understand why you would ask it from the article. However, that is not the case. Remember we are collaborating with Avacta (AVCT) "Affimers" and Aptamer Group "Aptamers" for evaluation of their virus capturing capability with ModernWater as a distribution channel for one part. But we are working for a complete end-to-end solution for clients who have a desire to meet instant alert solutions.

I tried to post this here, but it was too long so I wrote an article on LinkedIn. https://www.linkedin.com/pulse/instant-alert-wastewater-covid19-gerard-brandon Opening the economy with #COVID19 requires an instant daily low-cost test that can be done as an entry/exit to ships/aeroplanes/offices/hospitals/countries/arenas. Combined with an early warning system for the community, in wastewater #Integumen #ModernWater #Microtox #wastewatertesting will roll back the damage done with this highly infectious disease

@Matt, I have been informed that the change to the Annual Report has been made and uploaded. I have checked to see myself, so warrants properly priced on Page 58 here https://www.integumen.com/wp-content/uploads/2020/08/Integumen-plc-Annual-Report-2019-1.pdf

@iantobach The name was originally derived from the the word "integumentary" relating to an enveloping or external layer or covering (as of skin, hair, scales, feathers, or cuticle) of an organism or one of its parts. When new management took over the company was very focused on selling beauty and skin care products,had an oral hygiene tongue cleaner (I know !!!!!) and of course Labskin.

It certainly is getting way beyond that, but before we considered changing the name we wanted to let shareholders (new and old) that the company, that was a mess when we took over, had been turned around. We did not want to hide the past, but fix it. We have done that now and considering a name change in due course to reflect where we are, what we are doing and where we are going.

@Matt thank you for pointing that out. You are correct in saying that the warrants on that page should be 2p. The placing at the time was 1.5p, so this is a typo and we will arrange for this to be corrected.

Morning All

I am intrigued about comments on the warrant exercise. Just 2 weeks ago, based on our growth rate, we secured a £3m loan facility and only drew down £1.5m indicating the following:

"This comprehensive loan facility has been designed to align with the Company's guided revenue projection and provide sufficient working capital to maintain and build on that growth well into 2021"

The share price jumped from 2p to an average of 2.8p and just as we are delighted for shareholders who exercised their warrants, the Company receives £571k today plus £34k last week into our bank. We did not solicit, nor account for them in our working capital requirement in our Annual Report or when we secured the loan two weeks ago. Yet here we are with a chunk (technical term :) ) of extra capital in our war chest to speed our growth.

As a former fund manager (back in the 90's) I reported my NAV every month to clients. Fund managers operate on a fee plus percentage gain. So the Net Asset Value (NAV) at the end of each month is important to investors and for promotion of the fund to new clients.

60% of these warrants were exercised by our largest shareholder and as a successful fund manager (3 out of 71 in the Barclays List) they will have a very nice NAV improvement this month because of their profit on the exercised shares. Contrary to what private investors assume but long term holders are happy to increase their holding for the above reason.

As for warrants, these are disclosed in the annual report and in shareholder circulars when issued, so easily known to any and all investors. No additional shares are issued, they already are accounted for by the warrants disclosed.

First issue on the delay is that nobody has ever dealt within the constraints of COVID19 before. Second, it is technical and frustrating as hell when minor queries that are easily accessible in a normal audit are not so, following a year when two subsidiaries were liquidated and former employees are no longer around, to provide the support that would make for a normal audit. Hope that helps

@Stu from my days as an engineer, Legionella risk, particularly in nursing homes posed a risk of dormant water at elevated temperature. However, at 55 degrees, which is the maximum recommended hot water temperature in a nursing home, there is no risk as the bacteria dies off.

The risk of the virus derived from rivers for cooling towers is slim to nil for a number of reasons. The first thing to consider is this. Many studies have shown that the highest risk of virus transmission from an individual is up to 8 days from becoming infected.

Next. While sewage contains the virus from feacal matter shed by the infected person, it generally is not in a tranmissive state, where the lipid encapsulating the virus is damaged.

Generally when water is taken in for processing it undergoes some treatment, after testing. This can be as simple as UV lighting, but in general is not allowed to be processed without some testing.

Here too, temperature plays a major role in killing the virus, so above 25 degrees the chance of the virus surviving is slim to nil.

Ordinarily a scientist would finish by saying that is not proof, but it has a high probability of the above being accurate. Hope that helps

@Stu you have highlighted a fundamental issue when it comes to commercialising a platform technology, in any company. Part of the reason it is possible to acquire high value technology is because of the temptation to chance many rainbows, and miss all of them, is so great.

The hardest, and most valuable lesson, is to learn to say no and focus on the one area that places your technology at the core of a solution to large (preferably) societal problems, so you have the ability to own, control and dominate your market.

That's pretty much the Integumen philosophy. Our common denominator is bacteria, virus and toxins. That is the base on which Labskin was designed to host. That is the core reason for Modern Water's detection system. The enhance both with artificial intelligence.

Once you own that market, you continue to improve the value to existing clients which in turn increase revenue per client, lowering marketing costs and securing recurring revenues as you expand the global footprint of the offer.

That was quick. posted before I got a chance to myself

Too true.... But it is just that things got in the way to let me finish is before today.

@Daygrow and everyone who is either a shareholder or those who follow the Integumen project, thank you for the well wishes, that are normally sent to a person, but in this case I welcome that Integumen is certainly part of a lot of peoples lives, from employees to shareholders.

As well as on other social media, I will later today publish a blog post that I had intended to get out this morning, but this last couple of weeks have been extremely busy. There is so. so much going on even I have find it mind-blowing half the time.

I don't want to spoil the content, but I will talk about past and what I can about the future within AIM and EU MAR rules, so please bear with me. It's all good by the way.

Once again thanks for the support

Gerry

Over time, tests, the data collected and analysed will provide virus load and indicate probability of size of outbreak. But other advance, as a result of the work so far, will extend that further. News on that to follow, but it should be yet another game-changing outcome of our real-time Novel Sensor.

@ImABeliever

Answers to 1 and 2 is that I suspect they spent too much time and resources on a project that could not be sustained. Chasing large contracts over years is a big boys game, for the likes of utility companies, not small cap companies with limited resources. So they ran out of runway is how I see it and as a result had no alternative but to close it down. As for Gibraltar I have no idea what they are doing, as it all is in the past.

The Company had 40 employees in their 2018 annual report. That is now a fraction of that amount and a lot have been removed since the new business model was put in place. Its just not the same company it was 4 months ago.

All the old Board have gone. However executives with long term institutional knowledge play a key role in transformation from old to new. Those who stayed have been instrumental in help change and skillset that were missing have been added, some skills missing from team members have been supplemented with new contracts, collaboration, revenue sharing and all in all it is a lean machine today.

If they had sold off the monitoring division I would not have bought in, and brought in investors with the new Board. That is the gem. It is exactly the same hidden gem that was in Integumen when my team invested in that, when 6 months before we took over, Labskin was offered for sale, or was to be moth-balled. That became the core holding of Integumen.

I expect the Monitoring division to be the gem in Modern Water and currently it is being transformed to achieve similar goals.

It's always the little things that are overlooked. I am a believer, as I invested and take my fees only in shares from Modern Water.

@PitseaAbe and @Paulcon62 First I want to thank you for having faith in coming back in and supporting the turnaround of Modern Water. It takes a certain mindset to leave behind the past in a share and buy in to the future of a business model. I very much admire and respect that and conspiracy theories aside, the Gibraltar contract was cancelled in August last year, when one of the subsidiaries went into liquidation. https://polaris.brighterir.com/public/modern_water/news/rns/story/wvlk90r

I got involved in Modern Water in March on the Board and investing along with many Integumen shareholders because as a mechanical engineer I understand the technology. However, the real reason is that they had the Monitoring division, with a 30 year gold standard Brand in water contamination detection, with thousands of installations in more than 60+ countries.

Here is an under-exploited sales, marketing and distribution channel for the SKIN real-time identification of pathogens. When we got involved, we did not foresee COVID19, just a hidden gem. Now the monitoring division is core to the value in the future of Modern Water. The rest of the technology is wonderful, but at the core is the accumulated 30+ years of knowledge and a distribution channel next to none in even very large water utility corporations. This will be the value in the future of Modern Water, working with Real-Time novel sensor to identify pathogenic virus and bacteria in drinking and wastewater with Integumen's already successful 4-second ID of bacteria and using proven Avacta Affimers and Aptamer Group Aptamers that have been successful in capturing SARS-CoV-2 for their clients in recent weeks.

So, again I thank you for your support. We are doing our best, working with the virus to deliver the results this quarter

@Steven.P this is within the Integumen Group

As a shareholder it works for me too. When Cellulac provided short term funding it did not cover the requirement for working capital to keep going at the same pace we seen at the beginning of the year and with our COVID 19 virus detection project, which is progressing well, our growth can now continue at the same pace well into 2021.

This removes all resource limited obstacles on expansion programs for Labskin and for the real-time wastewater based epidemiology novel sensor that is being tested at the moment. All the pieces of the consortium puzzle are now in place.

Next week is the 2nd anniversary since new management took over. This puts the icing on the cake and we can close off the historical chapter and dig deep on our expertise now on the verge of a major breakthrough on COVID19